Encephalitis - Pipeline Review, H2 2018

  • ID: 4590338
  • Report
  • 36 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • CEL-SCI Corp
  • Knight Therapeutics Inc
  • Sage Therapeutics Inc
  • MORE
Encephalitis - Pipeline Review, H2 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Encephalitis - Pipeline Review, H2 2018, provides an overview of the Encephalitis (Central Nervous System) pipeline landscape.

Encephalitis is an inflammation of the brain tissue. There are two main types of encephalitis: primary and secondary. Primary encephalitis occurs when a virus directly infects the brain and spinal cord. Secondary encephalitis occurs when an infection starts elsewhere in the body and then travels to brain. Causes include common viruses, childhood viruses, and arboviruses. Risk factors include age and weak immune systems. Symptoms include fever, headache, vomiting, stiff neck, coma and hallucinations. Treatment includes pain killers, corticosteroids, anticonvulsants and sedatives.

Report Highlights:

This latest pipeline guide Encephalitis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Encephalitis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Encephalitis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Encephalitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I and Preclinical stages are 1 and 6 respectively.

Encephalitis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Encephalitis (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Encephalitis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Encephalitis (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Encephalitis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Encephalitis (Central Nervous System)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Encephalitis (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Encephalitis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • CEL-SCI Corp
  • Knight Therapeutics Inc
  • Sage Therapeutics Inc
  • MORE
Introduction

Report Coverage

Encephalitis - Overview

Encephalitis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Encephalitis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Encephalitis - Companies Involved in Therapeutics Development

CEL-SCI Corp

Knight Therapeutics Inc

Sage Therapeutics Inc

Encephalitis - Drug Profiles

Amphotericin B sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CEL-1000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

miltefosine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pneumococcal (13-valent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pneumococcal (23-valent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Polyglactin 370 for Encephalitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAGE-718 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Encephalitis - Dormant Projects

Encephalitis - Product Development Milestones

Featured News & Press Releases

Jun 28, 2017: FDA Grants Profounda Orphan Drug Designation for treatment of Granulomatous Amebic Encephalitis (GAE) with Miltefosine

Dec 17, 2016: Profounda receives FDA orphan-drug designation for the Treatment of Primary Amebic Meningoencephalitis (PAM) with Miltefosine

Aug 24, 2016: Orlando patient survives Primary Amebic Meningoencephalitis using Profoundas drug Impavido (miltefosine)

Feb 26, 2013: National Institutes of Health Supports Acea’s Research

Aug 22, 2011: Dr. James McKerrow, efficacy of Corifungin vs. Naegleria

Aug 22, 2011: FDA Grants 2nd Orphan drug designation

Feb 10, 2010: Dr. Jose Vazquez presents poster at ICAAC

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Encephalitis, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Encephalitis - Pipeline by CEL-SCI Corp, H2 2018

Encephalitis - Pipeline by Knight Therapeutics Inc, H2 2018

Encephalitis - Pipeline by Sage Therapeutics Inc, H2 2018

Encephalitis - Dormant Projects, H2 2018

List of Figures

Number of Products under Development for Encephalitis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • CEL-SCI Corp
  • Knight Therapeutics Inc
  • Sage Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll